Patent Row

  • Relief for Pfizer on anti-cancer drug June 4, 2013

    Chennai: In a relief to pharma major Pfizer, the Intellectual Property Appellate Board in Chennai has set aside the revocation of the patent of the company's anti-cancer drug 'Sutent'. The Board has asked the Patent Office to consider the entire matter afresh in a time-bound manner, which had twice revoked...
  • Patent row: HC refuses interim relief to Merck April 5, 2013

    New Delhi: The Delhi High Court on Friday refused to grant interim relief on a patent row to US pharmaceuticals major Merck Sharp and Dohme (MSD) which sought a restraint on Indian firm Glenmark Pharmaceuticals manufacturing and marketing anti-diabetes drugs Zita and Zita-Met. Justice Rajiv Sahai Endlaw dismissed the interim...
  • 'Has to be a balance between innovation, affordability of drugs' April 1, 2013

    After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...
  • Will now invest in India 'cautiously', says Novartis April 1, 2013

    Mumbai: Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the...
  • 'SC ruling discourages innovative drug discovery' April 1, 2013

    New Delhi: Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. "Novartis has never been granted an original patent for Glivec in India. We strongly believe...
  • SC verdict on Novartis's cancer drug Glivec today April 1, 2013

    New Delhi: The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec - the anti-cancer drug manufactured by Swiss pharma-giant Novartis - priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of...